Are synovial biopsies of diagnostic value?
© BioMed Central Ltd 2003
Received: 14 July 2003
Accepted: 18 August 2003
Published: 2 October 2003
Skip to main content
© BioMed Central Ltd 2003
Received: 14 July 2003
Accepted: 18 August 2003
Published: 2 October 2003
Synovial tissue is readily accessible by closed needle or arthroscopic biopsy. These techniques provide adequate tissue for most diagnostic requirements. Examination of synovial tissue can assist in the diagnosis of some joint infections, and in several atypical or rare synovial disorders. Histological confirmation is not normally required for diagnosis of the common forms of inflammatory arthritis, including rheumatoid arthritis (RA). In patients with either established or early RA, immunohistological measures of inflammation in synovial tissue are associated with clinical measures of disease activity, may predict the clinical outcome, and change in response to treatment. Surrogate markers of disease activity and outcome that have been identified in synovial tissue include components of the cellular infiltrate, and several mediators of inflammation and matrix degradation. There is evidence that the very early introduction of disease-modifying therapy inhibits progressive structural damage maximally. Clinicians exploiting this 'window of opportunity' therefore require very early indicators of the diagnosis and outcome in patients who present with an undifferentiated inflammatory arthritis. Some immunohistological features have been described that distinguish patients who are likely to develop progressive RA and who might benefit most from early aggressive therapeutic intervention. In this regard, the inclusion of pharmacogenomic and proteomic techniques in the analysis of synovial tissue presents some exciting possibilities for future research.
Early histopathological studies of rheumatoid arthritis (RA) were based on tissue samples obtained at surgery or at postmortem examination. In 1932 a technique for obtaining non-surgical synovial tissue for diagnostic purposes, using a dental nerve extractor that was introduced into the joint through a large-calibre needle, was first proposed . The introduction of this technique to clinical practice was never described. About 20 years later, early experiences with needle biopsy of the synovium were published [2, 3]. It was suggested that the procedure was safe and practical for use in both hospital wards and outpatient clinics. However, because of their wide bore and the need for an incision, these prototype biopsy needles tended to cause significant trauma to the penetrated tissues. In 1963, Parker and Pearson described a simplified 14-gauge needle that did not require a skin incision . They published their experience of 125 procedures, almost all from the suprapatellar pouch of the knee joint, with a very high yield of adequate tissue for analysis. No serious complications were encountered. For about 30 years, the Parker–Pearson needle, or a modification of it [5, 6], remained the instrument of choice when acquiring synovial tissue for diagnostic or research purposes.
Arthroscopic techniques, which enable the selection of synovial tissue under direct vision, were also developed primarily to assist in the diagnosis of arthritis . Early studies by rheumatologists suggested a lack of association between the arthroscopic findings and clinical, laboratory and radiological features of arthritis [8, 9]. More recently there has been an upsurge in the use of arthroscopic techniques by rheumatologists, particularly those interested in the pathogenesis of arthritis and the effects of new therapeutic strategies . Initially, arthroscopy required hospitalisation and a general anaesthetic. The production of high-definition, small-bore arthroscopes (1–2.7 mm), and the development of local and regional anaesthesia protocols [11, 12], have permitted day-case arthroscopy to move from the operating theatre to procedure rooms, and even to the outpatient clinic .
Synovial biopsy is not normally required for routine diagnostic or therapeutic purposes in patients with established arthritis. However, examination of synovial tissue can assist in the diagnosis of some joint infections . In acute bacterial arthritis, the synovial membrane contains clusters or sheets of polymorphonuclear leukocytes. Bacteria can be demonstrated in synovial tissue by Gram's stain. Sometimes, cultures of synovial tissue may be positive even when blood and synovial fluid cultures have been negative. In chronic infections, such as tuberculosis and fungal diseases, characteristic synovial lesions may be focal, and multiple biopsies are advised. Mycobacterial granulomas in the synovium do not always demonstrate caseation. With appropriate staining, acid-fast organisms, fungi and spirochetes (Lyme disease and secondary syphilis) can be demonstrated. The presence of bacterial DNA in synovial biopsy samples can provide important information in the diagnosis of infectious arthritis .
Occasionally, the diagnosis of chronic sarcoidosis is established after synovial biopsy . The characteristic histological feature is a well-defined granuloma. The central area of the granuloma is occupied by lymphocytes, which are predominantly CD4+, and by mononuclear phagocytes and their progeny, including epithelioid cells and multinucleated giant cells. Caseation is absent, but a small area of fibrinoid necrosis may be present. The outer zone of the granuloma is formed by CD4+ and CD8+ lymphocytes, fibroblasts, mast cells and other immunoregulatory cells.
Both gout and pseudogout can demonstrate tophus-like deposits in synovial tissue . When handling tissues, special care is required to preserve the crystalline structures. Amyloid may be deposited in synovium in patients with primary amyloidosis, Waldenstrom's macroglobulinemin, multiple myeloma and adult cystic fibrosis . Arthropathy associated with ochronosis and haemachromatosis demonstrate characteristic histological features. Pigmented villonodular synovitis, multicentric reticulohistiocytosis and rare tumours of the synovial membrane require a biopsy for diagnosis.
Synovial biopsy can have a major role in the diagnosis of monarticular arthritis. A closed needle biopsy of the knee joint might provide sufficient tissue for histological, immunohistological and microbiological analysis. An open biopsy or needle arthroscopic biopsy is the procedure of choice when other joints are involved, and should be undertaken in the knee joint if closed needle biopsy fails to yield a diagnosis.
The diagnosis of RA after the chronic polyarticular manifestations have become established is usually based on characteristic clinical, radiological and serological manifestations. Histological confirmation is not required. The gross changes that are characteristic of RA result from chronic synovial inflammation. Typically, the surface of the synovium becomes hypertrophic and oedematous, with an intricate system of prominent villous fronds that extend into the joint cavity. Microscopic evaluation of synovial tissue inflammation in RA confirms marked cellular hyperplasia in the lining layer. T cells, plasma cells, macrophages, B cells, neutrophils, mast cells, natural killer cells and dendritic cells accumulate in the synovial sublining layer (reviewed in ). The appearances are not specific for RA. The dominant cell populations in the lining layer are fibroblast-like synoviocytes and macrophages, which release an array of proinflammatory cytokines and their inhibitors, promoting further intra-articular perturbations. There is abundant production of matrix metalloproteinases (MMPs), cysteine proteases and other tissue-degrading mediators, which accumulate in the synovial fluid and augment joint damage by interacting directly with exposed cartilage matrix. These features are present very early in the disease course. T cells and plasma cells are prominent in the synovial sublining layer. Perivascular T cell aggregates are observed in 50–60% of patients with RA. These aggregates can be surrounded by plasma cells. There are two basic patterns of T cell infiltration. First, perivascular lymphocyte aggregates can be found, which consist predominantly of CD4+ cells in association with B cells, few CD8+ cells, and dendritic cells. The second pattern of T cell infiltration is the diffuse infiltrate of T cells scattered throughout the synovium. A subset of the CD4+ T cells in synovial tissue is activated. A possible biological effect of activated perivascular T cells in the synovium is the stimulation of migrating macrophage populations through direct cell contact. This mechanism is known to stimulate macrophage production of cytokines and MMPs in vitro. Many of the synovial tissue T cells are, however, in a state of hyporesponsiveness. Interdigitating dendritic cells, which are potent antigen-presenting cells, are located in proximity to CD4+ T cells in the lymphocyte aggregates and near the intimal lining layer. In addition, macrophages and lymphocytes infiltrate the areas between the lymphocyte aggregates. The macrophages often constitute the majority of inflammatory cells in the synovial sublining layer. B cells constitute a small proportion of the total number of lymphocytes in the synovial sublining layer. However, numerous plasma cells may be present throughout the synovium, sometimes exceeding the number of infiltrating T cells.
An issue that frequently arises in the context of possible associations between synovial tissue immunohistology and progressive structural damage relates to the acquisition of tissue samples from a knee joint and the evaluation of radiographic images, usually of the hands and feet. Such studies make the assumption that the immunohistological appearances in a knee joint are representative of pathophysiological events occurring at other sites. Evidence to support this hypothesis comes from a study of patients with RA who underwent biopsy of a knee joint and a small upper-limb joint on the same day . Another important issue that requires consideration is the question of selection bias. This issue has been evaluated extensively, confirming that despite the degree of histological variation within a joint, representative measures of inflammation can be obtained by examining a limited area of tissue [20–23].
The intensity of the cellular infiltrate, the levels of activation and the amount of secreted products vary greatly between individual patients with RA and other arthropathies [20, 24, 25]. Many studies of synovial tissue have been reported that indicate associations between immunohistological features of inflammation and clinical measures of disease activity [20, 26, 27], as well as with local measures of synovitis . The immunohistological measures of synovitis observed in the knee joint are reflected in other joints from the same patient biopsied at the same time . Clinically uninvolved joints in patients with RA demonstrate similar immunohistological changes, although less intensely than in the affected joints [29, 30]. Serial synovial biopsies in open therapeutic studies and in randomised clinical trials showed that the immunohistological features of RA and other arthropathies change after treatment with disease-modifying anti-rheumatic drugs (DMARDs) [26, 31–37], oral corticosteroids  and targeted biological agents [39–42]. The mediators of inflammation that have been shown to change in therapeutic studies include mononuclear cell populations [26, 31, 32, 35, 36, 39, 40, 42], adhesion molecule expression [35, 36, 38–40, 42], levels of cytokine production [31, 33, 35, 36, 41] and MMPs [34, 36, 37]. Thus, synovial tissue analysis in patients with RA has revealed several surrogate markers of disease activity and response to treatment.
In contrast to the studies of disease status and response to treatment in patients with established arthritis, limited attention has been given to the study of the immunohistological appearances and associations with disease outcome. One cross-sectional analysis demonstrated significant correlations between the number of lining layer and sublining layer macrophages, but not other mononuclear cell populations, and joint damage scores in RA . A longitudinal study highlighted the association between the number of synovial tissue macrophages at baseline and increases in the joint damage scores over 1 year . Other investigators showed that the predominant change in the synovial tissue of patients in remission after treatment with DMARDs was a striking decrease in the number of macrophages . These observations are consistent with the hypothesis that chronic RA is a macrophage-mediated disorder and that a decrease in synovial macrophage content should be a primary aim of successful treatment.
Interleukin-10 (IL-10) is a chondroprotective cytokine and functions in part by inhibiting the production of TNF-α, IL-1 and MMPs (reviewed in ). Treatment of experimental models of arthritis with recombinant IL-10 inhibited both the incidence and the severity of disease. In a cross-sectional biopsy study, IL-10 mRNA levels were measured in synovial tissue from patients with erosive RA and compared with those in patients with chronic non-erosive arthritis . The patients with erosive RA were positive for IgM-rheumatoid factor (IgM-RF+) and had a mean disease duration of 16.8 years. The patients with non-erosive arthritis had a mean disease duration of 7 years, and most were seronegative. Synovial tissue IL-10 mRNA levels were significantly lower in the patients with erosive RA (P < 0.03). This observation from a cross-sectional analysis of patients with established RA was extended in a longitudinal study of IL-10 polymorphisms in 291 consecutive patients with early RA. During the first 6 years of follow-up, the increase in radiographic damage scores in the patients who were homozygous for the genotype -1082AA was significantly less than the increase in patients with the genotype -1082GG. The smaller number of erosions in patients with RA who had the -1082AA genotype could not be explained by other determinants of progressive joint damage, such as an increased concentration of IgM-RF, the presence of the shared epitope, or the baseline radiographic damage score. Taken together, these observations suggested that increased expression of IL-10 mRNA in synovial tissue might be required for protection against progressive erosive disease, and that patients with RA who have different IL-10 genotypes have a different disease course. Future research is necessary to confirm whether or not there is a baseline threshold of tissue IL-10 mRNA expression that will identify individual patients with early RA who are more likely to demonstrate an aggressive disease course.
Synovial angiogenesis, a mechanism that is central to synovial proliferation and pannus formation, is largely dependent on vascular endothelial growth factor (VEGF) . In a small study of patients with RA, synovial tissue samples were evaluated for the presence of VEGF at the time of joint replacement surgery and, on average, 10 years later . An association between the amount of VEGF production in endothelial cells and the rate of progressive joint damage was suggested. Further studies of proinflammatory cytokines, tissue-degrading enzymes, angiogenic factors and other mediators of inflammation and damage in the synovium, at the level of either gene expression or protein production, might reveal characteristics associated with a favourable or unfavourable outcome.
The approach to treating patients with early RA has changed substantially in recent years. In most centres, early arthritis refers to patients who present within 1 year of the onset of symptoms. This change has occurred for several reasons. First, there has been a growing recognition that irreversible structural damage can occur very early in the course of inflammatory arthritis . Second, the establishment of dedicated early arthritis clinics facilitates the early referral of patients with inflammatory arthritis . Third, there is a wider recognition of reliable diagnostic factors . Fourth, rheumatologists have access to effective therapeutic modalities that greatly reduce the rate of progressive joint damage [52–54]. Last, it has been established that DMARD therapy reduces the rate of progressive joint damage more effectively when introduced within 6 months of the onset of symptoms . It is therefore now standard practice to introduce conventional DMARDs, such as methotrexate, and even targeted biological therapies, as first-line treatments in patients with RA .
The presence of some autoantibodies, including IgM-RF and anti-citrulline-containing peptide (anti-CCP) antibody, facilitates an early diagnosis of RA . In addition, several clinical and laboratory factors at baseline reliably predict outcome. These include higher baseline joint counts, a high titre of IgM-RF, an elevated acute-phase response, the number of baseline erosions and the shared epitope . However, these factors were identified in large cohorts and do not always apply to individual patients. Some clinical investigators have developed algorithms that incorporate selected prognostic factors to predict outcome [59, 60].
Studies of synovial tissue to identify indicators of outcome in RA, and changes after treatment, have been necessarily limited in size in comparison with similar studies that evaluated clinical and serum factors. Synovial biopsy is an invasive procedure and, when performed at arthroscopy, is technically complicated and expensive. Quantification of changes with digital image analysis is also costly and requires considerable expertise. However, the pathophysiological events occurring in tissue are more likely than dispersed serum factors to reflect the clinical status and outcome in individual patients.
In a similar early synovitis cohort, the expression of MMP-2, MMP-9, MMP-14 and TIMP-2 (tissue inhibitor of metalloproteinases-2) was quantified in synovial tissue biopsies obtained at baseline . Radiographs of the hands and feet were repeated after 1 year. The synovial tissue samples from patients who developed joint erosions had significantly higher levels of MMP-2 than those from the patients who did not develop erosions (P = 0.04). There seemed to be considerable overlap between the groups, and the authors did not distinguish between MMP-2 expression in the lining and sublining layers. Nevertheless, the observation suggested that baseline tissue MMP-2 levels might be a marker for more aggressive synovial inflammation.
With the emergence of convincing scientific evidence that very early introduction of disease-modifying therapies inhibits progressive structural damage more effectively , it is inevitable that some patients who receive treatment will not meet the ACR criteria for RA and will have a self-limiting, non-progressive arthritis. Thus, clinicians will seek a balance between exploiting the early 'window of opportunity' in some patients, and delaying effective treatment until the appearance of sufficient diagnostic criteria in others. About 30% of patients have an undifferentiated inflammatory arthritis at the time of their first presentation to an early arthritis clinic . Similarly, a diagnosis of RA can be established in about 30% of patients. During the period of follow-up, many of the patients with undifferentiated arthritis will develop features that enable a diagnosis of RA, or other categories of arthritis. Several factors have been identified that distinguish groups of patients with undifferentiated arthritis who acquire a diagnosis of RA. Thus, the presence in the serum of anti-perinuclear factor , anti-RA33 , anti-Sa , anti-keratin , antifilaggrin  and anti-CCP antibodies  has been associated with the diagnosis or outcome of RA. In addition, high-titre antibody against serum amyloid A in patients attending an early arthritis clinic with undifferentiated arthritis was associated with a subsequent diagnosis of RA .
In another study, immunohistological differences between RA and other categories of arthritis were also observed in 71 patients, including 16 who had had RA for less than 12 months . The intensity of infiltration by both T and B cells, and differential expression of α V integrin, seemed to distinguish patients with RA from those with spondylarthritis and those with osteoarthritis. The disease duration of RA did not influence the findings. However, the immunohistological features highlighted in both of these studies seem insufficiently disease-specific for routine use as diagnostic markers.
The demonstration of intracellular citrullinated proteins in synovial tissue samples from 18 of 36 patients with RA, and in none of 52 patients with spondylarthritis, osteoarthritis and other categories of arthritis, suggested a useful method of discriminating RA from other inflammatory joint diseases . This observation was the first description of a specific histological marker for RA in synovial tissue. The specificity of intracellular citrullinated proteins to RA is the subject of continuing investigation, and it is clear that further biochemical characterisation of the citrullinated proteins present in the synovium of patients with RA, and other inflammatory joint diseases, is required [71, 72]. Nevertheless, the possibility that demonstrating intracellular citrullinated protein in synovial tissue might be a new tool for the early diagnosis of undifferentiated arthritis is an important prospect.
There is increasing emphasis on the need to recognise potentially erosive disease in patients presenting with early undifferentiated arthritis, before sufficient criteria for RA have evolved. It is likely that pathophysiological pathways that directly or indirectly result in bone and cartilage degradation are preferentially activated in articular tissues from the earliest phases of the disease. The recognition of enhanced proinflammatory or degradative pathways, or the downregulation of inhibitory factors, that participate in the progression or prevention of arthritis, is most likely to emerge from studies of articular tissues. The preliminary studies of synovial tissues reported here support this hypothesis. The inclusion of pharmacogenomic and proteomic techniques in the analysis of synovial tissue from patients with different categories and stages of arthritis presents some exciting possibilities for future research.
American College of Rheumatology
disease-modifying anti-rheumatic drugs
tumour necrosis factor-α
vascular endothelial growth factor